1306763-31-4

Basic information

• Product Name: (R)-tert-butyl (4-cyano-2,3-dihydro-1H-inden-1-yl)carbamate
• Synonyms: (R)-tert-butyl (4-cyano-2,3-dihydro-1H-inden-1-yl)carbamate;Carbamic acid,N-[(1S)-4-cyano-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester;tert-butyl (S)-(4-cyano-2,3-dihydro-1H-inden-1-yl)carbamate;CPD3774-A5;tert-butyl N-[(1S)-4-cyano-2,3-dihydro-1H-inden-1-yl]carbamate;Anti-MS;N-[(1S)-4-Cyano-2,3-dihydro-1H-inden-1-yl]carbamic acid 1,1-dimethylethyl ester
• CAS NO: 1306763-31-4
• Molecular Formula: C₁₅H₁₈N₂O₂
• Molecular Weight: 258.31562
• EINECS: -0
• Mol File: 1306763-31-4.mol

Chemical Properties

• Boiling Point: 411.9±44.0 °C(Predicted)
• Appearance: /
• Density: 1.15±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 11.86±0.20(Predicted)
• CAS DataBase Reference: (R)-tert-butyl (4-cyano-2,3-dihydro-1H-inden-1-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-tert-butyl (4-cyano-2,3-dihydro-1H-inden-1-yl)carbamate(1306763-31-4)
• EPA Substance Registry System: (R)-tert-butyl (4-cyano-2,3-dihydro-1H-inden-1-yl)carbamate(1306763-31-4)

Safety Data

• Hazardous Substances Data: 1306763-31-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-tert-butyl (4-cyano-2,3-dihydro-1H-inden-1-yl)carbamate is used as a chiral reagent for the synthesis of enantiomerically pure compounds. Its application is crucial in the development of single-enantiomer drugs, which can have significant advantages over racemates in terms of efficacy and safety.
Used in Chemical Synthesis:
(R)-tert-butyl (4-cyano-2,3-dihydro-1H-inden-1-yl)carbamate is used as a building block in the synthesis of various organic compounds, particularly those with chiral centers. Its unique structure allows for the creation of a wide range of molecules with potential applications in different industries.
Used in Research and Development:
In the field of research and development, (R)-tert-butyl (4-cyano-2,3-dihydro-1H-inden-1-yl)carbamate serves as an important compound for studying the effects of chirality on chemical reactions and the properties of molecules. This knowledge can be applied to improve the design and synthesis of new drugs and materials.
Used in Analytical Chemistry:
(R)-tert-butyl (4-cyano-2,3-dihydro-1H-inden-1-yl)carbamate can be employed as a chiral reference standard in analytical chemistry. It helps in the identification and quantification of enantiomers in samples, which is essential for understanding the stereochemistry of biologically active compounds.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1306763-57-4 (S)-1-amino-2,3-dihydro-1H-indene-4-carbonitrile hydrochloride 
• 1213099-69-4 (S)-(1-amino-2,3-dihydro-1H-indene-1-yl)-4-carbonitrile 
• 60899-34-5 4-cyano-2,3-dihydro-1H-inden-1-one 
• 15115-60-3 4-bromo-2,3-dihydroinden-1-one 

Downstream Products

• 1306760-86-0 5-(3-{(1S)-1-[(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-4-yl}-1,2,4-oxadiazol-5-yl)-2-[(propan-2-yl)oxy]benzonitrile 
• 1306763-62-1 (S)-tert-butyl 2-(tert-butyldimethylsilyloxy)ethyl-(4-(N-hydroxycarbamimidoyl)-2,3-dihydro-1H-inden-1-yl)carbamate 
• 1306763-57-4 (S)-1-amino-2,3-dihydro-1H-indene-4-carbonitrile hydrochloride 

Relevant articles and documents

IMPROVED PROCESS FOR THE PREPARATION OF OZANIMOD Α-AMINO COMPOUND

The present invention relates to an improved process for the preparation of optically chiral amino compound. The present invention particularly relates to the improved process for the preparation of (S)-1-amino-2,3-dihydro-1H-indene-4-carbonitrile, an important intermediate for the synthesis of ozanimod. The present invention more particularly relates to preparation of (S)-1-amino-2,3-dihydro-1H-indene-4- carbonitrile using 4-cyano-1-indanone and α-methylbenzylamine derivatives as starting materials. The present invention specifically relates to preparation of (S)-1- amino-2,3-dihydro-1H-indene-4-carbonitrile comprising diastereoselective chiral amine synthesis by protection with chiral auxiliary ?-methyl benzylamine derivatives followed by reduction and debenzylation.

COMPOUNDS AND METHODS FOR TREATING LUPUS

Methods for treatment of systemic lupus erythematosus (SLE" or "Lupus") by administration of a modulator of sphingosine-1-phosphate receptor subtype 1 (S1P1), as well as compositions and methods related to the same, wherein such S1P1 modulators have the f

DEUTERIUM-SUBSTITUTED OXADIAZOLES

Described are deuterated modulators of S1P1 receptors, pharmaceutical compositions thereof, and methods of use thereof.

SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH

Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided, including compounds which modulate subtype 1 of the S1P receptor, and methods of their therapeutic and/or prophylactic use in combination with at least one other medicament adapted for treatement of a malcondition for which activation of S1P1 is medically indicated, such as multiple sclerosis.

SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS

Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.